Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, Daniel P., Smith, Blake E., Burslem, George M., Buhimschi, Alexandru D., Hines, John, Jaime-Figueroa, Saul, Wang, Jing, Hamman, Brian D., Ishchenko, Alexey, Crews, Craig M.·2018·Cell Chemical Biology
DOI 10.1016/j.chembiol.2017.09.010

Cited by (965)

Items 601–700 of 965

  1. Preparation of von Hippel-Lindau (VHL) E3 ubiquitin ligase ligands exploiting constitutive hydroxyproline for benzylic amine protection
    Diana M. Soto-Martínez, Garrett D. Clements, John E. Díaz, J. BECHER, Robert C. Reynolds, Christina Ochsenbauer, Timothy S. Snowden · 2024 · RSC Advances
  2. Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
    Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, Chen‐Qian Liu, Mengyao Xu, Jian‐Xuan Sun, Ye An, Xing‐Yu Zhong, Lin-Tao Miao, Shaogang Wang et al. · 2024 · Biomedicine & Pharmacotherapy
  3. Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
    Junyi Zhao, Hongzhen Chen, Chao Liang · 2025 · Biomarker Research
  4. PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors
    Andrew D. Huber, Wenwei Lin, Kwan‐Young Jung, Shyaron Poudel, Guangwei Yang, Jing Wu, Allison Carrigan, Vishwajeeth Pagala, Wei Wang, Yingxue Fu et al. · 2025 · Nature Communications
  5. Deciphering phosphorylation TACtics: Advances in phosphorylation targeting strategies and bifunctional modalities
    Dong-Ting Ke, Zilong Zhan, Wenliang Zhang, Zhenyi Hu, Po‐Han Chen · 2026 · Cell chemical biology
  6. Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces
    Luca Torielli, Stefano Artin Serapian, Lara Mussolin, Elisabetta Moroni, Giorgio Colombo · 2022 · Journal of Chemical Information and Modeling
  7. Targeting Moonlighting Enzymes in Cancer
    Chunxu Lin, Mingyang Yu, Ximei Wu, Hui Wang, Min Wei, Luyong Zhang · 2024 · Molecules
  8. Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy
    Joseph A. Newman, Angeline E. Gavard, Nergis Imprachim, H. Aitkenhead, Hadley E. Sheppard, Robert te Poele, Paul Andrew Clarke, Mohammad Anwar Hossain, Louisa Temme, Hans J. Oh et al. · 2025 · Nature Communications
  9. Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive
    Laura Martina Luh, Ulrike Scheib, Katrin Juenemann, Lars Wortmann, Michael Brands, Philipp M. Cromm · 2020 · Angewandte Chemie
  10. Discovery of SOCS7 as a versatile E3 ligase for protein-based degraders
    Anaïs Cornebois, Marie Sorbara, Margot Cristol, Emmanuelle Vigne, Pierre Cordelier, Klervi Even-Desrumeaux, Nicolas Béry · 2024 · iScience
  11. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation
    Laura Márquez-Cantudo, Ana Ramos, Claire Coderch, Beatriz de Pascual‐Teresa · 2021 · Molecules
  12. From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
    Yvonne A. Nagel, Adrian Britschgi, Antonio Ricci · 2021 · Wiley eBooks
  13. Selection of DNA-encoded Chemical Libraries for Compounds that can Induce Protein Ubiquitination
    Cen Huang, Xing‐Yuan Liu, Xinyuan Wu, Ling Hua Meng, Xiaojie Lu, Xiaoyu Li · 2024 · ChemRxiv
  14. Atomic-Resolution Prediction of Degrader-mediated Ternary Complex Structures by Combining Molecular Simulations with Hydrogen Deuterium Exchange
    Dixon, Tom, MacPherson, Derek, Mostofian, Barmak, Dauzhenka, Taras, Lotz, Samuel, McGee, Dwight, Shechter, Sharon, Shrestha, Utsab R., Wiewiora, Rafal, McDargh, Zachary A. et al. · 2021
  15. Exploiting the DCAF16–SPIN4 interaction to identify DCAF16 ligands for PROTAC development
    Isabella A. Riha, Miguel A. Lorenzo Campos, Xiao‐Kang Jin, Fiona Y. Wang, Chenlu Zhang, Sara F. Dunne, Benjamin F. Cravatt, Xiaoyu Zhang · 2024 · RSC Medicinal Chemistry
  16. Small molecule targeted protein degradation via the UPS: venturing beyond E3 substrate receptors
    Renyu Guo, Fukang Yang, Emily C. Cherney · 2025 · RSC Medicinal Chemistry
  17. Construction of PROTAC molecules by the SuFEx reaction for inducing p300/CBP protein degradation
    Qiuyu Guo, Chunxia Yang, Xuyuan Liu, Jian Liu, Wei Zhang, Xiuhong Lu, Ning Ding · 2025 · Bioorganic & Medicinal Chemistry
  18. Molecular features defining the efficiency of bioPROTACs
    Dorothea Winkelvoß, David Vukovic, Anna-Carina Hänny, Luca Riermeier, Anto Udovcic, Jonas Kolibius, Annemarie Honegger, Peer R. E. Mittl, Erich Michel, Simon Hansen et al. · 2025 · Communications Biology
  19. High-throughput investigation of macromolecular interactions for drug development using spectral shift technology
    Charlotte E. Hunter, Ehmke Pohl, Stefanie Freitag · 2025 · Biophysical Reviews
  20. The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology
    Zhenzhen Li, Xiaoli Huang, Xuchi Zhao, Yunxiu Zhang, Ping Li · 2025 · Targets
  21. Spatiotemporally controlled protein degradation via NIR-activatable PROTAC platform
    Nan Wang, Wei Cong, Yurui Zhu, Huaxing Shen, Chao Liu, Honggang Hu, Man Pan · 2025 · Science China Chemistry
  22. Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
    Xinchen Lu, Quanyin Hu · 2026 · Bioconjugate Chemistry
  23. Proximity Binding Assay for PROTAC Ternary Complex Analysis
    Irene Ponzo, Alice Soldà, Charlotte Crowe, Göran Dahl, Tereza Jahodová, Andreas Heerwig, Stefan Geschwindner, Alessio Ciulli, Ulrich Rant · 2026 · ACS Sensors
  24. Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
    Charlotte Crowe, Alessio Ciulli · 2026 · Chemical Reviews
  25. Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation
    Tanja Lehmann, Hendrik Schneider, Jason Tonillo, Jennifer Schanz, Daniel F. Schwarz, Christian J. Schröter, Sebastian Jäger, Harald Kolmar, Stefan Hecht, Jan Anderl et al. · 2024 · Bioconjugate Chemistry
  26. Targeted Degradation of Protein Kinase A via a Stapled Peptide PROTAC
    Matthew K. Whittaker, George N. Bendzunas, Mahsa Shirani, Timothy J. LeClair, Bassem Shebl, Taylor C. Dill, Philip Coffino, Sanford M. Simon, Eileen J. Kennedy · 2024 · ACS Chemical Biology
  27. Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
    Zhenwu Li, Lalgudi S. Harikrishnan, Guozhang Xu, Debangshu Samanta, José C. Clemente, Lingying Leng, Wenbin Tu, Lin Yang, Liyue Huang, Mi Wang et al. · 2024 · Journal of Medicinal Chemistry
  28. Advanced PROTAC and Quantitative Proteomics Strategy Reveals Bax Inhibitor-1 as a Critical Target of Icaritin in Burkitt Lymphoma
    Peixi Zhang, Ziqing Zhang, Jie Li, Meng Kai Xu, Weiming Lu, Ming Chen, Jiaqi Shi, Qiaolai Wang, Hengyuan Zhang, Shi Huang et al. · 2024 · International Journal of Molecular Sciences
  29. Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations
    Hualong Mo, J. Y. Liu, Ting Yin, XuXu Cao, Zhiguang Su, Deng‐Gao Zhao, Yanyan Ma · 2025 · Journal of Medicinal Chemistry
  30. Identification of ligand linkage vectors for the development of p300/CBP degraders
    Duncan K. Brownsey, Ben C. Rowley, Evgueni Gorobets, Koichiro Mihara, Ranjan Maity, James W. Papatzimas, Benjamin S. Gelfand, Morley Donald Hollenberg, Nizar Jacques Bahlis, Darren J. Derksen · 2022 · RSC Medicinal Chemistry
  31. Methods to characterize and discover molecular degraders in cells
    Zhi Lin, Christina M. Woo · 2022 · Chemical Society Reviews
  32. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
    Muhammad Zafar Irshad Khan, Adila Nazli, Youlu Pan, Jian‐Zhong Chen · 2022 · Current Medicinal Chemistry
  33. Exploring the genetic space of the DNA damage response for cancer therapy through CRISPR ‐based screens
    Jordan Wilson, Joanna I. Loizou · 2022 · Molecular Oncology
  34. Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity
    Victoria G. Klein, Adam G. Bond, Conner Craigon, R. Scott Lokey, Alessio Ciulli · 2021
  35. Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3
    Martin Roatsch, Anja Vogelmann, Daniel Herp, Manfred Jung, Christian Adam Olsen · 2020 · ChemRxiv
  36. Utilizing Alkyne‐Nitrone Cycloaddition for the Convenient Multi‐Component Assembly of Protein Degraders and Biological Probes
    Shiou‐Ting Lin, Chien‐Hua Wang, Ailin Chen, Tsung‐Shing Andrew Wang · 2024 · Chemistry - A European Journal
  37. HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase
    Anne‐Christin Sarnow, Husam Nassar, Abdallah M. Alfayomy, Dina Robaa, Wolfgang Sippl · 2025 · Computers in Biology and Medicine
  38. Harnessing Chimeric Degrader Technologies for Antimicrobial Innovation
    Saikat Kumar Poddar, Kuntala Dey, Guangrong Zheng · 2025 · Journal of Medicinal Chemistry
  39. Design, Optimization, and Development of RIPK1 Degraders with Improved Pharmacokinetic and Pharmacodynamic Properties
    Dong Lu, Xin Qi Yu, Hanfeng Lin, Ran Cheng, Bin Yang, Min Zhang, Jingjing Chen, Feng Li, Xiaoli Qi, Jin Wang · 2025 · Journal of Medicinal Chemistry
  40. Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS
    Max M. Wang, Mihai Ioan Truica, Brayley S. Gattis, Julia Oktawiec, Vinay Sagar, Ananya A. Basu, Paul A. Bertin, Xiaoyu Zhang, Sarki Abba Abdulkadir, Nathan C. Gianneschi · 2026 · Nature Communications
  41. Assessing the suitability of deubiquitylases as substrates for targeted protein degradation
    Joel Tong, J. Monty Watkins, James M. Burke, Thomas J. Kodadek · 2026 · Cell chemical biology
  42. Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets
    Annoor Awadasseid, Rui Wang, Shishi Sun, Feng Zhang, Yanling Wu, Wen Zhang · 2024 · Biomedicine & Pharmacotherapy
  43. To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
    Diana Castagna, Benoit Gourdet, Roland Hjerpe, Philip MacFaul, Andrew Novak, Guillaume Révol, Étienne Rochette, Allan Michael Jordan · 2024 · Progress in medicinal chemistry
  44. Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance
    Kumarappan Chidambaram, A. Rekha, Ahsas Goyal, Mohit Rana · 2025 · Pathology - Research and Practice
  45. E3Docker: a docking server for potential E3 binder discovery
    Kejia Yan, Wangqiu He, Mingwei Pang, Xufeng Lu, Zhou Chen, Lianhua Piao, Han Zhang, Yu Wang, Shan Chang, Ren Kong · 2025 · Nucleic Acids Research
  46. Proteolysis Targeting Chimeras (PROTACs) Based on Promiscuous Kinase Inhibitor Synergistically Induce Cancer Cell Apoptosis Through Multiple Mechanisms
    Jiadai Zhai, Chuang Li, Sinan Wang, Bingxia Sun, Yuting Cui, Qingzhi Gao, Feng Sang · 2022 · ChemistrySelect
  47. Reevaluation of bromodomain ligands targeting BAZ2A
    Giulia Cazzanelli, Andrea Dalle Vedove, Eleonora Parolin, Vito D’Agostino, Andrea Unzue, Cristina Nevado, Amedeo Caflisch, Graziano Lolli · 2023 · Protein Science
  48. Catalytic Protein Inhibitors
    Thomas J. Kodadek · 2023 · Angewandte Chemie International Edition
  49. Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis
    Yibing Wang, Jianan Zheng, Yun Long, Wenyi Wu, Yutong Zhu · 2023 · Biochemical Pharmacology
  50. Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges
    Yuxuan Wang, Yanyi He, Qidong You, Lei Wang · 2024 · Drug Discovery Today
  51. Fluorophosphonate‐Based Degrader Identifies Degradable Serine Hydrolases by Quantitative Proteomics
    S. Denise Field, Wankyu Lee, Jason K. Dutra, Finley F. Serneo, Jon A. Oyer, Hua Xu, Douglas S. Johnson, Christopher W. am Ende, Uthpala I. Seneviratne · 2020 · ChemBioChem
  52. Development of CDK2 and CDK5 Dual Degrader TMX‐2172
    Mingxing Teng, Jie Jiang, Zhixiang He, Nicholas P. Kwiatkowski, Katherine A. Donovan, Caitlin E. Mills, Chiara Victor, John M. Hatcher, Eric S. Fischer, Peter Karl Sorger et al. · 2020 · Angewandte Chemie
  53. Prospect of ULK1 modulators in targeting regulatory T cells
    Young Jun Park, Jaebong Jang · 2022 · Bioorganic Chemistry
  54. The Advent of Directed Protein Degraders in Drug Discovery
    Mohamed Benchekroun · 2019 · Future Drug Discovery
  55. Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable photoPROTACs
    Patrick Pfaff, Kusal T. G. Samarasinghe, Craig M. Crews, Erick M. Carreira · 2019 · ChemRxiv
  56. Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
    Camilla Ruffilli, Sascha Röth, Noam Zelcer, Kévin Moreau · 2025 · Scientific Reports
  57. Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
    Madison Ambrose, Jeremy Lee, Aleem Syed, Zamal Ahmed, Guang Peng · 2025 · Frontiers in Drug Discovery
  58. Dynamic characteristics of proteolysis-targeting chimera systems revealed by in silico computations
    Kexin Xu, Jingxuan Ge, Rongfan Tang, Tingjun Hou, Huiyong Sun · 2025 · Current Opinion in Structural Biology
  59. Nanotechnology-based strategies for overcoming clinical limitations of PROTACs in cancer therapy
    Hanhee Cho, Jinseong Kim, Ho-Yeon Lee, Hyein Kang, Kwangmeyung Kim · 2025 · Journal of Materials Chemistry B
  60. Targeted tau protein degradation: a promising therapeutic approach for tauopathies
    Narjes Baazaoui, Mohammad Yahya Alfaifi, Ali Abdullah Shati, Rania Ben Saad, Stefanıa Garzoli · 2025 · Neuroscience
  61. A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System
    Sophie R. Thomas, Thomas Iellici, Mihyun Park, Elisabeth Klaus, Andrea Bileck, Christopher Gerner, Samuel M. Meier, Angela Casini · 2026 · ACS Chemical Biology
  62. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
    Nikola Knoll, Nouri Neamati, Aykut Üren · 2026 · ACS Pharmacology & Translational Science
  63. Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment
    Priyanka Gupta, Sumit Dutta, Prashant Kumar, Monika Kaushik, Sumel Ashique, Mithun Bhowmick · 2025 · Current Drug Discovery Technologies
  64. RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS
    Kevin D. Freeman‐Cook, Robert L. Hoffman · 2023 · Medicinal chemistry reviews
  65. Chemical rewiring of ubiquitination by degraders and their selectivity routes
    Rory Whelan, Cristina Mayor‐Ruiz · 2024 · Nature Structural & Molecular Biology
  66. PROTAC® technology and potential for its application in infection control
    Maria Zakharova, М. В. Чудинов · 2024 · Fine Chemical Technologies
  67. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer
    Peter D. Zang, Allen Seylani, Evan Y. Yu, Tanya Barauskas Dorff · 2024 · Expert Review of Anticancer Therapy
  68. Design and synthesis of JNK1-targeted PROTACs and research on the activity
    Yue Guo, Fengling Liu, Man Chi, Hewen Qian, Ye Zhang, Yaxia Yuan, Shurong Hou, Xiabin Chen, Lei Ma · 2024 · Bioorganic Chemistry
  69. Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics
    Atharva Anand Mahajan, Gauri Panzade, Tiyasa Bhuniya, Purbasha Das, Bidyabati Bhattacharjee, Sagnik Das, Ankita Chowdhury, Kashmira Chakraborty, Sudeepta Guha, Anushka Samant et al. · 2024 · Current Problems in Cancer
  70. Discovery of First-in-Class BAZ2A/B and BAZ2B-Selective Degraders
    Leonardo Palaferri, Iván Cheng‐Sánchez, Katherine A. Gosselé, Dominika Zielińska, Cristina Nevado · 2025 · ACS Medicinal Chemistry Letters
  71. High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
    Kristin M. Riching, Sarah D. Mahan, Marjeta Urh, Danette L. Daniels · 2020 · Journal of Visualized Experiments
  72. Establishment and validation of a sensitive LC–MS/MS method for the quantification of KRASG12C protein PROTAC molecule LC‐2 in rat plasma and its application to in vivo pharmacokinetic studies of LC‐2 PEGylated liposomes
    Yu Wang, Zhiyu Wang, Xiaowen Wang, Xiao Li, Xueqi Liu, Xiaoyu Zhang, Sha Liu · 2023 · Biomedical Chromatography
  73. PROTACs in gynecological cancers: Current knowledge and future potential as a treatment strategy
    Fatemeh Movahed, Zahra Ourang, Razieh Neshat, Wael Sheet Hussein, Anwar Salih Saihood, Maythum Shallan Alarajy, Donya Zareii · 2024 · Pathology - Research and Practice
  74. Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
    Jayapal Reddy Mallareddy, Lin Yang, Wan‐Hsin Lin, Ryan W. Feathers, Jennifer R. Ayers-Ringler, Ezequiel J. Tolosa, Amritha G. Kizhake, Smitha Kizhake, Sydney P. Kubica, Lidia Boghean et al. · 2025 · RSC Advances
  75. Exploiting Folding and Degradation Machineries To Target Undruggable Proteins: What Can a Computational Approach Tell Us?
    Stefano Artin Serapian, Alice Triveri, Filippo Marchetti, Matteo Castelli, Giorgio Colombo · 2021 · ChemMedChem
  76. Chemoproteomics-Enabled Ligand Screening Yields Covalent RNF114-Based Degraders that Mimic Natural Product Function
    Mai Luo, Jessica N. Spradlin, Scott M. Brittain, Jeffery M. McKenna, John A. Tallarico, Markus Schirle, Thomas J. Maimone, Daniel K. Nomura · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  77. Computational Modeling of PROTAC Ternary Complexes and Linker Design
    Sven A. Miller, Grigorii V. Andrianov, Victoria Mischley, Khadija A. Wharton, Jesse J. Chen, John Karanicolas · 2022 · Wiley eBooks
  78. Targeted Protein Degradation for Agricultural Applications: Rationale, Challenges, and Outlook
    Denis Fourches, Joseph R. Pilotte, Brian E. Watts, Daniel J. Saltzberg, Robert M. Cicchillo · 2025 · ACS Bio & Med Chem Au
  79. Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders
    Maria Hanl, Felix Feller, Irina Honin, Kathrin Tan, Martina Miranda, Linda Schäker‐Hübner, Nico Bückreiß, Matthias Schiedel, Michael Gütschow, Gerd Bendas et al. · 2025 · ACS Pharmacology & Translational Science
  80. Predicting PROTAC off-target effects via warhead involvement levels in drug–target interactions using graph attention neural networks
    Yutong Hu, Kieran Didi, Adam P. Cribbs, Jianfeng Sun · 2025 · Computational and Structural Biotechnology Journal
  81. Discovery of KRAS-G12D degraders via exploration of various E3 ligases
    Hyerin Yim, Xiangyang Song, Yue Zhong, Jacqueline Hu, Yan Xiong, Jian Jun Jin · 2026 · European Journal of Medicinal Chemistry
  82. Discovery of SKP2‐Recruiting PROTACs for Target Protein Degradation
    Guanjun Dong, Aima Huang, Ziqing Zhao, Bikai Lai, Xin Pan, Huiyu Yang, Xiaohan Xu, Tianwei Wang, Fangchen Zhao, Zhimin Zhang et al. · 2026 · Advanced Science
  83. Altered residence time as a cause of drug resistance
    Brian M. Farrell, Markus A. Seeliger · 2026 · Current Opinion in Structural Biology
  84. Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
    Lieen Ma, Ning Wang, Jingjing Zhu, Lingjie Wu, Shan He, Bin Zhang · 2026 · Acta Pharmaceutica Sinica B
  85. Advantages of PROTACs in achieving selective degradation of homologous protein families
    Luxi Yang, Xinfei Mao, Jingyi Zhang, Jing Shu, Wenhai Huang, Xiaowu Dong, Yinqiao Chen, Mingfei Wu · 2026 · Beilstein Journal of Organic Chemistry
  86. Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers
    Lingying Leng, Liyue Huang, Wenbin Tu, Wei Jiang, Rohan Kalyan Rej, Srinivasa Rao Allu, Yu Wang, Mi Wang, Jelena Tošović, Meilin Wang et al. · 2026 · Journal of Medicinal Chemistry
  87. Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
    Tingting Yao, Zheng Zhou, Guangji Wang, Zhe-ying Zhu, Xi-Nuo Li · 2026 · Acta Pharmacologica Sinica
  88. Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)
    Mainak Banerjee, Alexandre Detappe, Twan Lammers · 2026 · Advanced Drug Delivery Reviews
  89. Tumor immune cell targeting chimeras reprogram tumor-associated macrophages
    Mariko Morimoto, David S. Roberts, Ru M. Wen, Ell Handy, Eric E. Peterson, Grace M. Stepek, Nicholas A. Till, James D. Brooks, Carolyn Ruth Bertozzi · 2026 · Nature Chemical Biology
  90. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
    Tiana Huynh, Sonia Rodrı́guez, Alexey Valeryevich Danilov · 2024 · Molecular Cancer Therapeutics
  91. Structure-based PROTAC Design
    Darryl B. McConnell · 2020 · Royal Society of Chemistry eBooks
  92. Preclinical Studies of PROTACs in Hematological Malignancies
    Ota Fuchs, Radka Bokorová · 2021 · Cardiovascular & Haematological Disorders - Drug Targets
  93. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs
    Daniel P. Bondeson, Blake E. Smith, Alexandru D. Buhimschi · 2021 · Methods in molecular biology
  94. Process Development for the Synthesis of BI 1702135: A Concise Design Enabled by Selective Acylation of a 2-Aminobenzimidazole Intermediate
    Jiang‐Ping Wu, Weitong Dong, Chengsheng Chen, Alexander V. Sienkiewicz, Phouvieng Beyer, Jun Wang, Nizar Haddad, Jon C. Lorenz, Jonathan T. Reeves, Matthew H. Bunner et al. · 2023 · Organic Process Research & Development
  95. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia
    Yuan E. Zhang, Xin Wu, Xueyan Sun, Jun Yang, Chang Xin Liu, Guotao Tang, Xiaoyong Lei, Honglin Huang, Junmei Peng · 2023 · Mini-Reviews in Medicinal Chemistry
  96. Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
    Iván Cheng‐Sánchez, Katherine A. Gosselé, Leonardo Palaferri, Eleen Laul, Gionata Riccabella, R.K. Bedi, Yaozong Li, Anna Müller, Ivan Corbeski, Amedeo Caflisch et al. · 2024 · JACS Au
  97. Recent advances in targeted degradation in the RAS pathway
    Zhiming Ge, Zisheng Fan, Wei He, Guizhen Zhou, Yidi Zhou, Mingyue Zheng, Sulin Zhang · 2025 · Future Medicinal Chemistry
  98. PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
    Anthony Feral, Guillaume Laconde, Muriel Amblard, Nicolas Masurier · 2020 · Advanced Therapeutics
  99. Targeting STK33: From Inhibition to Degradation
    Siying Zhong, Joanne Wayne · 2021 · Future Medicinal Chemistry
  100. Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and Avidity
    Satomi Imaide, Kristin M. Riching, Vesna Vetma, Claire Whitworth, Scott J. Hughes, Nicole B. Trainor, Sarah D. Mahan, Nancy Murphy, Kwok-Ho Chan, Andrea Testa et al. · 2020 · ChemRxiv